Literature DB >> 18483755

Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia.

J I Garcia Paez1, F M Tengan, A A Barone, A S Levin, S F Costa.   

Abstract

Severe infections caused by Stenotrophomonas maltophilia are associated with high mortality, and strategies to improve the clinical outcome for infected patients are needed. A retrospective cohort study of patients with bloodstream infection (BSIs) and pneumonia caused by S. maltophilia was conducted. Multivariate analysis was performed to access factors associated with 14-day mortality. A total of 60 infections were identified. Among these, eight (13%) were pneumonias and 52 were BSIs; 33.3% were primary, 13% were central venous catheter (CVC)-related and 40% were secondary BSIs. Fifty-seven (85%) patients had received previous antimicrobial therapy; 88% had CVC, 57% mechanical ventilation and 75% were in the intensive care unit at the onset of infection. Malignancy (45%) was the most frequent underlying disease. The mean of the Acute Physiology and Chronic Health Evaluation II (APACHE II) scores was 17 and for the Sepsis-related Organ Failure Assessment (SOFA) score, it was 7 points. The overall and 14-day mortality were, respectively, 75% and 48%. Forty-seven (78%) patients were treated and, of these, 74% received trimethoprim-sulfamethoxazole. Independent risk factors associated with mortality were SOFA index >6 points (0.005) and septic shock (0.03). The Kaplan-Meier estimations curves showed that patients with APACHE II score >20 and SOFA score >10 had a survival chance of, respectively, less than 8% and less than 10% (P<or=0.001) at 21 days after the first positive S. maltophilia culture. Our results suggest that the independent factors associated with outcome in patients with infection caused by S. maltophilia are septic shock and higher SOFA index.

Entities:  

Mesh:

Year:  2008        PMID: 18483755     DOI: 10.1007/s10096-008-0518-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  24 in total

1.  Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia.

Authors:  Gokhan Metan; Omrum Uzun
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia.

Authors:  Chung-Hsu Lai; Chih-Yu Chi; Hsin-Pai Chen; Te-Li Chen; Chorng-Jang Lai; Chang-Phone Fung; Kwok-Woon Yu; Wing-Wai Wong; Cheng-Yi Liu
Journal:  J Microbiol Immunol Infect       Date:  2004-12       Impact factor: 4.399

3.  Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors.

Authors:  L S Elting; N Khardori; G P Bodey; V Fainstein
Journal:  Infect Control Hosp Epidemiol       Date:  1990-03       Impact factor: 3.254

4.  Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study.

Authors:  Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals.

Authors:  S Tsiodras; D Pittet; Y Carmeli; G Eliopoulos; H Boucher; S Harbarth
Journal:  Scand J Infect Dis       Date:  2000

6.  Attributable mortality of Stenotrophomonas maltophilia bacteremia.

Authors:  Esin Senol; Jeffrey DesJardin; Paul C Stark; Laurie Barefoot; David R Snydman
Journal:  Clin Infect Dis       Date:  2002-05-24       Impact factor: 9.079

7.  [Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia].

Authors:  María Dolores del Toro; Jesús Rodríguez-Baño; Luis Martínez-Martínez; Alvaro Pascual; Ramón Pérez-Canoa; Evelio J Perea; Miguel Angel Muniain
Journal:  Enferm Infecc Microbiol Clin       Date:  2006-01       Impact factor: 1.731

8.  Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes.

Authors:  R R Muder; A P Harris; S Muller; M Edmond; J W Chow; K Papadakis; M W Wagener; G P Bodey; J M Steckelberg
Journal:  Clin Infect Dis       Date:  1996-03       Impact factor: 9.079

9.  Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

Authors:  A J Morrison; K K Hoffmann; R P Wenzel
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

10.  Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome.

Authors:  Saad Nseir; Christophe Di Pompeo; Hélène Brisson; Florent Dewavrin; Stéphanie Tissier; Maimouna Diarra; Marie Boulo; Alain Durocher
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more
  20 in total

1.  Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay.

Authors:  L A Ruiz; A Gómez; C Jaca; L Martínez; B Gómez; R Zalacain
Journal:  Infection       Date:  2010-09-29       Impact factor: 3.553

2.  Type II Secretion-Dependent Degradative and Cytotoxic Activities Mediated by Stenotrophomonas maltophilia Serine Proteases StmPr1 and StmPr2.

Authors:  Ashley L DuMont; Sara M Karaba; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

Review 3.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

4.  Characterization of maltocin P28, a novel phage tail-like bacteriocin from Stenotrophomonas maltophilia.

Authors:  Jian Liu; Peng Chen; Congyi Zheng; Yu-Ping Huang
Journal:  Appl Environ Microbiol       Date:  2013-07-08       Impact factor: 4.792

5.  Stenotrophomonas maltophilia strains replicate and persist in the murine lung, but to significantly different degrees.

Authors:  Ruella Rouf; Sara M Karaba; Jenny Dao; Nicholas P Cianciotto
Journal:  Microbiology (Reading)       Date:  2011-05-05       Impact factor: 2.777

6.  A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada.

Authors:  Prenilla Naidu; Stephanie Smith
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

7.  Stenotrophomonas maltophilia Serine Protease StmPr1 Induces Matrilysis, Anoikis, and Protease-Activated Receptor 2 Activation in Human Lung Epithelial Cells.

Authors:  Ashley L DuMont; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

8.  Microbial Ecosystem Analysis in Root Canal Infections Refractory to Endodontic Treatment.

Authors:  Luiz Carlos Feitosa Henriques; Luciana Carla Neves de Brito; Warley Luciano Faria Tavares; Ricardo Palmier Teles; Leda Quércia Vieira; Flávia Rodrigues Teles; Antônio Paulino Ribeiro Sobrinho
Journal:  J Endod       Date:  2016-07-01       Impact factor: 4.171

9.  Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.

Authors:  Kosuke Sumida; Yong Chong; Noriko Miyake; Tomohiko Akahoshi; Mitsuhiro Yasuda; Nobuyuki Shimono; Shinji Shimoda; Yoshihiko Maehara; Koichi Akashi
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

10.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Nikki Jahnke; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.